These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 9359746)

  • 21. Phenotypic and genotypic analysis of biologically cloned human immunodeficiency virus type 1 isolates from patients treated with zidovudine and lamivudine.
    Stoeckli TC; MaWhinney S; Uy J; Duan C; Lu J; Shugarts D; Kuritzkes DR
    Antimicrob Agents Chemother; 2002 Dec; 46(12):4000-3. PubMed ID: 12435711
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination of drugs and drug-resistant reverse transcriptase results in a multiplicative increase of human immunodeficiency virus type 1 mutant frequencies.
    Mansky LM; Pearl DK; Gajary LC
    J Virol; 2002 Sep; 76(18):9253-9. PubMed ID: 12186909
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lamivudine-resistant human immunodeficiency virus type 1 variants (184V) require multiple amino acid changes to become co-resistant to zidovudine in vivo.
    Nijhuis M; Schuurman R; de Jong D; van Leeuwen R; Lange J; Danner S; Keulen W; de Groot T; Boucher CA
    J Infect Dis; 1997 Aug; 176(2):398-405. PubMed ID: 9237704
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Zidovudine resensitization and dual HIV-1 resistance to zidovudine and lamivudine in the delta lamivudine roll-over study.
    Masquelier B; Descamps D; Carrière I; Ferchal F; Collin G; Denayrolles M; Ruffault A; Chanzy B; Izopet J; Buffet-Janvresse C; Schmitt MP; Race E; Fleury HJ; Aboulker JP; Yeni P; Brun-Vézinet F
    Antivir Ther; 1999; 4(2):69-77. PubMed ID: 10682151
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Limited development and progression of resistance of HIV-1 to the nucleoside analogue reverse transcriptase inhibitor lamivudine in human primary macrophages.
    Aquaro S; Svicher V; Ceccherini-Silberstein F; Cenci A; Marcuccilli F; Giannella S; Marcon L; Caliò R; Balzarini J; Perno CF
    J Antimicrob Chemother; 2005 Jun; 55(6):872-8. PubMed ID: 15845785
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased drug susceptibility of HIV-1 reverse transcriptase mutants containing M184V and zidovudine-associated mutations: analysis of enzyme processivity, chain-terminator removal and viral replication.
    Naeger LK; Margot NA; Miller MD
    Antivir Ther; 2001 Jun; 6(2):115-26. PubMed ID: 11491416
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase.
    Tisdale M; Kemp SD; Parry NR; Larder BA
    Proc Natl Acad Sci U S A; 1993 Jun; 90(12):5653-6. PubMed ID: 7685907
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Crystal structures of Zidovudine- or Lamivudine-resistant human immunodeficiency virus type 1 reverse transcriptases containing mutations at codons 41, 184, and 215.
    Chamberlain PP; Ren J; Nichols CE; Douglas L; Lennerstrand J; Larder BA; Stuart DI; Stammers DK
    J Virol; 2002 Oct; 76(19):10015-9. PubMed ID: 12208978
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lamivudine or stavudine in two- and three-drug combinations against human immunodeficiency virus type 1 replication in vitro.
    Merrill DP; Moonis M; Chou TC; Hirsch MS
    J Infect Dis; 1996 Feb; 173(2):355-64. PubMed ID: 8568296
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Structures of Tyr188Leu mutant and wild-type HIV-1 reverse transcriptase complexed with the non-nucleoside inhibitor HBY 097: inhibitor flexibility is a useful design feature for reducing drug resistance.
    Hsiou Y; Das K; Ding J; Clark AD; Kleim JP; Rösner M; Winkler I; Riess G; Hughes SH; Arnold E
    J Mol Biol; 1998 Nov; 284(2):313-23. PubMed ID: 9813120
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vivo emergence of drug-resistant mutations at less than 50 HIV-1 RNA copies/mL that are maintained at viral rebound in longitudinal plasma samples from human immunodeficiency virus type-1-infected patients on highly active antiretroviral therapy.
    Elbeik T; Hoo BS; Campodonico ME; Dileanis J; Fay FF; Bortolozzi RL; Benetti MS; Fay OH; Marlowe N; Petrauskene O; Chernoff D; Smith L; Ng VL
    J Hum Virol; 2001; 4(6):317-28. PubMed ID: 12082398
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human immunodeficiency virus-infected persons with mutations conferring resistance to zidovudine show reduced virologic responses to hydroxyurea and stavudine-lamivudine.
    Montaner JS; Mo T; Raboud JM; Rae S; Alexander CS; Zala C; Rouleau D; Harrigan PR
    J Infect Dis; 2000 Feb; 181(2):729-32. PubMed ID: 10669364
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Three-drug combination of MKC-442, lamivudine and zidovudine in vitro: potential approach towards effective chemotherapy against HIV-1.
    Piras G; Nakade K; Yuasa S; Baba M
    AIDS; 1997 Mar; 11(4):469-75. PubMed ID: 9084794
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mutations associated with lamivudine-resistance in therapy-naïve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.
    Selabe SG; Lukhwareni A; Song E; Leeuw YG; Burnett RJ; Mphahlele MJ
    J Med Virol; 2007 Nov; 79(11):1650-4. PubMed ID: 17854040
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Concomitant combination therapy for HIV infection preferable over sequential therapy with 3TC and non-nucleoside reverse transcriptase inhibitors.
    Balzarini J; Pelemans H; Karlsson A; De ClercQ E; Kleim JP
    Proc Natl Acad Sci U S A; 1996 Nov; 93(23):13152-7. PubMed ID: 8917560
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antiretroviral efficacy and virological profile of a zidovudine/lamivudine/tenofovir disoproxil fumarate combination therapy in antiretroviral-naive patients.
    Masquelier B; Neau D; Boucher S; Lavignolle-Aurillac V; Schrive MH; Recordon-Pinson P; Ragnaud JM; Fleury H
    Antivir Ther; 2006; 11(6):827-30. PubMed ID: 17310827
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Frequency of drug-resistant variants of HIV-1 coexistent with wild-type in treatment-naive patients of India.
    Sachdeva N; Sehgal S; Arora SK
    MedGenMed; 2005 Jul; 7(3):68. PubMed ID: 16369294
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genotypic and phenotypic resistance under zidovudine and lamivudine therapy in human immunodeficiency virus-infected children.
    Funk M; Linde R; Braner HJ; Groeschel B; Kornhuber B; Kreuz W
    Eur J Pediatr; 1999 Jan; 158(1):86-7. PubMed ID: 9950320
    [No Abstract]   [Full Text] [Related]  

  • 39. Diminished selection for thymidine-analog mutations associated with the presence of M184V in Ethiopian children infected with HIV subtype C receiving lamivudine-containing therapy.
    Averbuch D; Schapiro JM; Lanier ER; Gradstein S; Gottesman G; Kedem E; Einhorn M; Grisaru-Soen G; Ofir M; Engelhard D; Grossman Z
    Pediatr Infect Dis J; 2006 Nov; 25(11):1049-56. PubMed ID: 17072129
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-infected patients in Spain.
    Gómez-Cano M; Rubio A; Puig T; Pérez-Olmeda M; Ruiz L; Soriano V; Pineda JA; Zamora L; Xaus N; Clotet B; Leal M
    AIDS; 1998 Jun; 12(9):1015-20. PubMed ID: 9662197
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.